Biosensors in Antimicrobial Drug Discovery: Since Biology until Screening Platforms
Bioprospecting development and consulting, Bogotá, Colombia
- *Corresponding Author:
- Juan Bueno
MD, MSc, Bioprospecting development and consulting
E-mail: [email protected]
Received Date: August 27, 2014; Accepted Date: October 27, 2014; Published Date: November 03, 2014
Citation: Bueno J (2014) Biosensors in Antimicrobial Drug Discovery: Since Biology until Screening Platforms. J Microb Biochem Technol S10:002. doi: 10.4172/1948-5948.S10-002
Copyright: © 2014 Bueno J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Antimicrobial drug resistance is a current public health problem, which is compounded by the misuse of antibiotics in medical practice and the emergence of Multidrug-Resistant (MDR) microorganisms. Therefore it is necessary to develop new anti-infective drugs and implement new methodologies able to establish the Antimicrobial Susceptibility (AST) in field and the point-of-care. In this sense biosensors is a promising technology that can detect MDR strains and small molecules in various samples, these devices have the advantages that can be miniaturized for obtain portability, rapidity, and cost-effectiveness. The aim of this work is to present the applications of biosensors technology in antimicrobial drug discovery, since cell based biosensors and cell culture on chips, considering metabolic interactions of the microbial world and the pharmacological response to be inhibited by compounds with promising activity with the end of design antimicrobial drug screening platforms robust, automatable and reproducible.